Advancing mRNA Medicines to Fight and Prevent Disease

Moderna is driven by our mission to deliver on the promise of mRNA science to create a new generation of transformative medicines for patients. We are currently advancing mRNA clinical studies on our development candidates to address serious unmet needs across several therapeutic areas and multiple diseases. Clinical (human) trials are now underway for several of our investigational mRNA vaccines and therapeutics that may have the potential to treat or prevent rare diseases, viruses and cancers. 

Moderna is actively recruiting participants to join our clinical trials by evaluating investigational mRNA therapies and vaccines for the treatment or prevention of Methylmalonic Acidemia (MMA), Cytomegalovirus (CMV), cancers and other diseases. We have provided links to our clinical trial listings on www.clinicaltrials.gov, where you can find more information, including details on eligibility criteria and clinical trial locations for each study. You can also view our full list of mRNA clinical trials below. 

Below is a list of clinical trials for which Moderna is actively recruiting participants. We have provided links to the study listings on www.clinicaltrials.gov, where you can find more information, including details on eligibility criteria and clinical trial locations.

If you are seeking additional information about our clinical trials, please email clinicaltrials@modernatx.com.

Actively Recruiting mRNA Clinical Trials

mRNA Prophylactic Vaccines


Disease Program Study Phase Study Focus More Info
Cytomegalovirus (CMV)  

mRNA-1647

 Phase 1 Safety, reactogenicity, and immunogenicity of Cytomegalovirus Vaccines mRNA-1647 in Healthy Adults clinicaltrials.gov
Zika  

mRNA-1893

 Phase 1 Safety, Tolerability, and Immunogenicity of Zika Vaccine mRNA-1893 in Healthy Flavivirus Seropositive and Seronegative Adults clinicaltrials.gov

 

mRNA Cancer Vaccines


Disease Program Study Phase Study Focus More Info
Solid tumors  

mRNA-4157

 Phase 1 Safety, Tolerability, and Immunogenicity of mRNA-4157 Alone in Subjects with Resected Solid Tumors and in Combination With Pembrolizumab in Subjects With Unresectable Solid Tumors (KEYNOTE-603) clinicaltrials.gov
Melanoma  

mRNA-4157

 Phase 2 An Efficacy Study of Adjuvant Treatment with the Personalized Cancer Vaccine mRNA-4157 and Pembrolizumab in Patients With High-Risk Melanoma (KEYNOTE-942) clinicaltrials.gov

 

mRNA Intratumoral Immuno-Oncology


Disease Program Study Phase Study Focus More Info
Advanced / metastatic
solid tumors
or lymphoma		  

mRNA-2416

 Phase 1 Dose Escalation Study of mRNA-2416 for Intratumoral Injection to Patients with Advanced Malignancies clinicaltrials.gov
Relapsed/Refractory
solid tumors
malignancies
or lymphoma		  

mRNA-2752

 Phase 1 Dose Escalation Study of mRNA-2752 for Intratumoral Injection to Patients with Advanced Malignancies clinicaltrials.gov

 

mRNA Systemic Secreted & Cell Surface Therapeutics


Disease Program Study Phase Study Focus More Info
Chikungunya virus  

mRNA-1944

 Phase 1 Safety, tolerability, pharmacokinetics and pharmacodynamics of mRNA-1944 in healthy adults clinicaltrials.gov

 

mRNA Systemic Intracellular Therapeutics


Disease Program Study Phase Study Focus More Info
Methylmalonic Acidemia  

mRNA-3704

 Phase 1/2 Open Label Study of mRNA-3704 in Patients With Isolated Methylmalonic Acidemia clinicaltrials.gov
Methylmalonic Acidemia, Propionic Acidemia  

mRNA-3704
mRNA-3927

 Natural History Study Longitudinal, exploratory, natural history
study of patients with MMA due to
mut deficiency and PA		 clinicaltrials.gov